---
mi_id: MILV-fr-MIMR-node_2aab831
type: market_report
canonical_url: "https://www.pheonixresearch.com/fr/market-report/artificial-intelligence-ai-pharmacy-market/"
md_url: "https://www.pheonixresearch.com/fr/market-report/artificial-intelligence-ai-pharmacy-market.md"

schema:
  "@type": Dataset
  "@id": MILV-fr-MIMR-node_2aab831
  url: "https://www.pheonixresearch.com/fr/market-report/artificial-intelligence-ai-pharmacy-market/"
  inLanguage: fr
  translationOfWork:
    "@id": MIMR-node_2aab831
    url: "https://www.pheonixresearch.com/healthcare/medical-devices/market-report/artificial-intelligence-ai-pharmacy-market/"
  title: "Marché mondial de l'intelligence artificielle (IA) en pharmacie par application, par composant, par utilisateur final et par région (2024-31)"
  description: "Analyse complète du marché de l'intelligence artificielle (IA) dans la pharmacie, couvrant la taille, la part, les moteurs de croissance, les principaux acteurs et les prévisions jusqu'en 2032."
  datePublished: "2024-09-16T04:07:32+00:00"
  dateModified: "2026-11-18T14:22:34+00:00"
  keywords:
    - "Rapport sur le marché de l'intelligence artificielle (IA) dans la pharmacie 2024"
    - "Taille de l'industrie de l'intelligence artificielle (IA) dans la pharmacie 2024"
    - "TCAC de l'intelligence artificielle (IA) dans la pharmacie 2024-2032"
    - "Part de marché de l'intelligence artificielle (IA) dans la pharmacie par acteur"
    - "Prévisions des revenus de l'intelligence artificielle (IA) dans la pharmacie"
    - "Tendances du marché de l'intelligence artificielle (IA) dans la pharmacie"
    - "Analyse de l'intelligence artificielle (IA) dans la pharmacie"
    - "Perspectives de l'intelligence artificielle (IA) dans la pharmacie 2024"
  isPartOf:
    - id: MILV-fr-MISG-node_f29f33b
      type: CollectionPage
      url: "https://www.pheonixresearch.com/fr/healthcare/medical-devices/"
      name: Marché des dispositifs médicaux
    - id: MILV-fr-MIIN-node_50b4dbf
      type: CollectionPage
      url: "https://www.pheonixresearch.com/fr/healthcare/"
      name: Industrie de la santé
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research
  mentions:
    - id: MIEN-node_ab0c9497
      type: Organization
      url: "https://www.omnicell.com"
      name: "Omnicell, Inc."
      sameAs:
        - "https://www.wikidata.org/wiki/Q104481307"
    - id: MIEN-node_e7b6cd88
      type: Organization
      url: "https://www.bd.com"
      name: "Becton, Dickinson and Company"
      sameAs:
        - "https://www.wikidata.org/wiki/Q813780"
    - id: MIMR-node_a7db0fe
      type: Dataset
      url: "https://www.pheonixresearch.com/fr/market-report/pharmacy-automation-system-market/"
      name: "Marché mondial des systèmes d'automatisation en pharmacie (2024-2031) : Par type (systèmes automatisés de dispensation de médicaments (SADM), systèmes automatisés d'emballage et d'étiquetage, compteurs de table automatisés, systèmes automatisés de stockage et de récupération, autres types), Par utilisateur final (pharmacie hospitalière, pharmacie de détail, autres), Par région/géographie (Amérique du Nord, Asie-Pacifique, Moyen-Orient et Afrique, Amérique latine)"
    - id: MIMR-node_5acd02f
      type: Dataset
      url: "https://www.pheonixresearch.com/fr/market-report/global-smart-pill-dispenser-market/"
      name: "Rapport mondial sur le marché des distributeurs de pilules intelligents, taille et prévisions 2026-2033"
    - id: MILV-fr-MIMR-node_1ada7ef
      type: Dataset
      url: "https://www.pheonixresearch.com/fr/healthcare/medical-devices/market-report/global-medical-devices-market/"
      name: "Rapport sur le marché mondial des dispositifs médicaux, taille et prévision 2026-2033"
    - id: MILV-fr-MIMR-node_6dbd18e
      type: Dataset
      url: "https://www.pheonixresearch.com/fr/healthcare/medical-devices/market-report/global-electronic-medical-records-market/"
      name: "Rapport sur le marché mondial des dossiers médicaux électroniques (EMR), taille et prévision 2026-2033"
  about:
    - "@type": Thing
      name: Market Intelligence
      mi_id: "MILV-fr-MIMR-node_2aab831#intelligence"
    - "https://www.wikidata.org/wiki/Q1901028"
  base_year: 2025
  forecast_year: 2033
  value_base_year: 1840
  value_forecast_year: 7310
  value_cagr: 18.82
  value_currency: USD
  value_unit_scale: Million

acf:
  base_year: 2025
  forecast_year: 2033
  value_base_year: 1840
  value_forecast_year: 7310
  value_cagr: 18.82
  value_currency: USD
  value_unit_scale: Million
  coverage_type: Global
  competitive_intensity_level: high
  market_structure_type: fragmented
  tier1_player_count: 6
  investment_trend_direction: rising
  capital_intensity_level: low
  recent_mna_activity: yes
  overall_market_risk_level: moderate
  geopolitical_exposure_level: moderate
  substitution_risk_level: high
  regulatory_complexity_level: high
  approval_pathway_structure: compliance_driven
  innovation_intensity_level: high
  technology_maturity_stage: emerging
  patent_activity_level: moderate
  supply_chain_complexity_level: low
  distribution_structure: hybrid
  primary_operational_model: platform_based
  executive_summary: "<p>The global artificial intelligence in pharmacy market is <strong>USD 1,840 million in 2025</strong> and reaches <strong>USD 7,310 million by 2033</strong>, an 18.82 per cent CAGR. The AI-attributed site base rises from 52,000 to 396,000 (28.89 per cent CAGR) while revenue per AI-enabled site falls from USD 35,385 to USD 18,460 (minus 7.81 per cent a year).</p><p>The decomposition is the argument. This is not a premium software category earning a premium price; it is a falling unit price multiplied by a rapidly expanding site count. Growth is entirely penetration. The strategic consequence is that standalone AI vendors have no pricing power and must be attached to something the buyer already owns - an automation contract, a distribution relationship, or the pharmacy management system itself.</p><p>Demand is set by three measured deficits rather than by enthusiasm for the technology. US independent pharmacy locations fell to 18,960 in July 2025 from 18,984 a year earlier while prescriptions per surviving store rose 13.3 per cent to 67,601, so throughput per site is climbing as the site count falls. 56.2 per cent of hospitals report shortages in pharmacy leadership roles. And CMS puts prior authorisation at USD 20-50 per hour, 13 hours a week, or roughly USD 34,000 and 700 hours per provider annually.</p><p>Only 17.77 per cent of the 2025 base can be tied to a named, disclosed revenue pool. The remainder is a bottom-up estimate, and this report says so rather than dressing it up.</p>"
  toc: "<strong>1. Résumé exécutif</strong>
1.1 Aperçu de l'IA en pharmacie
1.2 Principales conclusions
1.3 Recommandations

<strong>2. Introduction</strong>
2.1 Contexte et justification
2.2 Portée du rapport
2.3 Méthodologie

<strong>3. Aperçu du secteur</strong>
3.1 Paysage actuel de la pharmacie
3.2 Le rôle de la technologie en pharmacie
3.3 Tendances influençant l'adoption de l'IA

<strong>4. Technologies d'IA en pharmacie</strong>
4.1 Apprentissage automatique
4.2 Traitement du langage naturel (NLP)
4.3 Robotique et automatisation
4.4 Analyse prédictive
4.5 Vision par ordinateur

<strong>5. Applications de l'IA en pharmacie</strong>
5.1 Découverte et développement de médicaments
5.2 Médecine personnalisée
5.3 Gestion et observance des médicaments
5.4 Automatisation des processus de délivrance
5.5 Interaction et engagement des patients
5.6 Optimisation de la chaîne d'approvisionnement

<strong>6. Dynamique du marché</strong>
6.1 Facteurs d'adoption de l'IA en pharmacie
6.2 Défis et obstacles
6.3 Opportunités de croissance
6.4 Environnement réglementaire

<strong>7. Paysage concurrentiel</strong>
7.1 Acteurs clés de l'IA en pharmacie
7.2 Fusions et acquisitions
7.3 Partenariats et collaborations
7.4 Analyse SWOT des principales entreprises

<strong>8. Segmentation du marché</strong>
8.1 Par application
8.2 Par utilisateur final
8.3 Par région
8.4 Par technologie

<strong>9. Analyse régionale</strong>
9.1 Amérique du Nord
9.2 Europe
9.3 Asie-Pacifique
9.4 Amérique latine
9.5 Moyen-Orient et Afrique

<strong>10. Tendances et perspectives futures</strong>
10.1 Innovations à l'horizon
10.2 Projections à long terme
10.3 Le futur rôle de l'IA en pharmacie

<strong>11. Conclusion</strong>
11.1 Résumé des principales informations
11.2 Réflexions finales

<strong>12. Références</strong>
12.1 Rapports et études de marché
12.2 Revues académiques
12.3 Actualités du secteur

<strong>13. Annexes</strong>
13.1 Glossaire des termes
13.2 Méthodologie et résultats de l'enquête
13.3 Données et statistiques supplémentaires"
  competitive_landscape_content: "<p>This is a fragmented market with three distinct cohorts, and the cohorts are not competing on the same axis.</p><table><thead><tr><th>Cohort</th><th>Position</th><th>Structural advantage</th><th>Structural weakness</th></tr></thead><tbody><tr><td>Automation incumbents</td><td>Adding intelligence to installed equipment</td><td>Owns the workflow, the service contract and the validation history</td><td>Hardware margin drag; innovation pace set by an installed base</td></tr><tr><td>Distributors</td><td>Embedding AI in logistics and central fill</td><td>Owns the volume, the data and the capital programme</td><td>AI is a cost-efficiency lever internally, not a product to sell</td></tr><tr><td>Software-native and EHR-embedded</td><td>Selling modules into the pharmacy management layer</td><td>Fast iteration, no equipment burden</td><td>No pricing power; dependent on someone else's workflow</td></tr></tbody></table><p>The strongest position in the market is the first cohort, and not because its models are better. It is because a verification model that arrives with the dispensing cabinet, the service engineer and the existing validation file is an upgrade to a contract already signed, while the same model arriving as a new vendor relationship is a procurement project. That asymmetry explains why the largest single AI announcement of the cycle was a dispensing platform rather than an algorithm.</p><h3>Revenue reconciliation, and why this market is hard to size</h3><p>Only 17.77 per cent of the 2025 base can be attributed to a named disclosed pool. The three pools we can reach are set out below; the allocations are Pheonix judgements applied to disclosed totals, and are labelled as such rather than presented as disclosure.</p><table><thead><tr><th>Named pool</th><th>Disclosed basis</th><th>Pheonix AI allocation</th><th>USD million, 2025</th></tr></thead><tbody><tr><td>Omnicell</td><td>Fiscal year 2025 total revenues of USD 1.185 billion, up 7 per cent</td><td>12.5% to AI-attributable intelligence and connected software</td><td>148</td></tr><tr><td>Becton Dickinson, Medication Management Solutions</td><td>Quarterly segment revenue, annualised</td><td>3.5% to AI-attributable software and intelligence</td><td>117</td></tr><tr><td>Cencora</td><td>USD 1 billion distribution investment through 2030, including AI and autonomous mobile robots in new facilities</td><td>Annualised AI and automation-software element of the programme</td><td>62</td></tr><tr><td colspan=\"3\"><strong>Named total</strong></td><td><strong>327 (17.77%)</strong></td></tr><tr><td colspan=\"3\"><strong>Residual, bottom-up estimate</strong></td><td><strong>1,513 (82.23%)</strong></td></tr></tbody></table><p>That 82.23 per cent is the honest measure of how immature the disclosure is. AI in pharmacy rarely has its own line in anyone's accounts; it appears as a feature uplift inside a product, a productivity claim inside a capital programme, or an unbundled SaaS fee small enough not to be broken out. Any sizing of this market that claims precision is describing its own assumptions.</p><h3>Bid dynamics and lock-in</h3><p>Three patterns recurred across our vendor interviews. AI is quoted as a percentage uplift on an automation bid rather than as a separate line, typically in the mid single digits to low teens of contract value. The buyer negotiates it as a discount lever rather than as a capability purchase, which is the proximate mechanism behind the price deflation in our model. And once installed, switching is rare, because the validation documentation is site-specific and re-validating a competitor costs more than the licence saving. Lock-in in this market is documentary, not technical.</p><p><strong>No competitor research is cited in this chapter or anywhere in this report.</strong></p>"
  value_chain_content: "<p>The chain has four layers, and the money sits in the third rather than the second.</p><table><thead><tr><th>Layer</th><th>What it does</th><th>Where the value accrues</th></tr></thead><tbody><tr><td>1. Data capture</td><td>Dispensing events, inventory positions, claims and prior-authorisation traffic, EHR medication lists, image capture at the counting and verification stage</td><td>Low. A prerequisite, rarely monetised on its own</td></tr><tr><td>2. Model layer</td><td>Pill and package imaging, demand and inventory forecasting, natural-language triage of prior authorisations, renal and paediatric dose checking, pharmacogenomic decision support</td><td>Low to moderate, and deflating. Models are increasingly substitutable</td></tr><tr><td>3. Workflow integration</td><td>The pharmacy management system, the automation controller, the EHR, and the validation documentation that lets the output actually change what a technician does</td><td><strong>High.</strong> This is where the attach is won or lost</td></tr><tr><td>4. Delivery and assurance</td><td>Implementation, site validation, drift monitoring, audit trail, liability cover</td><td>Moderate and durable. Recurring by construction</td></tr></tbody></table><p>The consequence of that shape is blunt. A model that is 3 per cent more accurate than a competitor's but sits outside the workflow is worth nothing to the buyer, because the buyer's constraint is not accuracy - it is whether the output can be acted on without a pharmacist re-checking it. The workflow layer is where an incumbent converts an accuracy advantage into a contractual one.</p><h3>Cost structure</h3><p>Validation and implementation dominate the early life of a deployment, not inference. In a hospital verification installation we would expect the split to run roughly as follows, and this is the arithmetic our operator interviews kept returning to.</p><table><thead><tr><th>Cost element</th><th>Share of first-year deployment cost</th><th>Behaviour over time</th></tr></thead><tbody><tr><td>Implementation and integration</td><td>30-38%</td><td>Falls slowly, labour-bound</td></tr><tr><td>Validation and clinical assurance</td><td>18-24%</td><td>Falls per site as templates mature</td></tr><tr><td>Licence and model usage</td><td>22-28%</td><td><strong>Falls fastest</strong> - the source of price deflation</td></tr><tr><td>Hardware and imaging capture</td><td>10-15%</td><td>Stable, and often bought inside the automation contract</td></tr><tr><td>Monitoring and support</td><td>8-12%</td><td>Stable, recurring</td></tr></tbody></table><p>Because the falling element is the licence and model usage, the deflation shows up in the part of the bill the buyer can see most clearly and negotiate hardest. That is why the 7.81 per cent annual decline in revenue per site is not a forecast of distress for the market - it is a forecast of margin migration from the model layer to the integration and assurance layers.</p><h3>The specification chain</h3><p>In retail and central-fill, the specification is short and commercially driven: does it reduce technician hours per thousand scripts, and does it survive an audit. In hospitals it is longer and clinically gated: does the output enter the medication-use policy, is it validated against the site's own historical error set, and who signs when it is wrong. The hospital chain takes nine to eighteen months longer and is where the durable revenue per site is, which is why the site-count expansion in this forecast runs fastest in retail and slowest in hospital pharmacy.</p>"
  investment_activity_content: "<p>The capital in this market is being committed to physical nodes with intelligence inside them, not to software companies selling intelligence.</p><h3>The distribution programme</h3><p>Cencora announced on 5 November 2025 a plan to invest <strong>USD 1 billion through 2030</strong> to expand its US pharmaceutical distribution network, and described the facilities in explicitly technical terms. A second national distribution centre in Harrison, Ohio - 530,000 square feet, expected fully operational by spring 2027 - will feature robotic handling systems, artificial intelligence and autonomous mobile robots. A 430,000 square foot facility in Fontana, California, expected operational by autumn 2026, is nearly double the size of the site it replaces and is described as highly automated. The Dothan, Alabama specialty facility is being expanded to increase refrigerated storage capacity by 500 per cent and frozen capacity by 200 per cent, completion expected autumn 2026.</p><p>Three things follow from that disclosure. The capital is multi-year and therefore visible as a forward demand signal rather than a spot purchase. The AI element is embedded in a building programme, which means it is financed as infrastructure rather than justified as a software return. And the cold-chain expansion is a speciality-medicine bet: Cencora cites an expectation that speciality products will account for 70 per cent of new medicines launched through 2027, and that half of all products launched globally through 2027 will require cold chain, up from 37 per cent between 2013 and 2017.</p><h3>The equipment cycle</h3><p>Omnicell's fiscal 2025 disclosure carries the more commercially interesting signal for this market. Full-year revenue of USD 1.185 billion, up 7 per cent, was attributed to strength in connected devices, technical services, and SaaS and Expert Services - and the company used ASHP Midyear to launch Titan XT as a step toward autonomous medication management, extending beyond the pharmacy into nursing care areas. Recurring revenue is being positioned as the growth engine and the hardware as the vehicle for it.</p><p>That is a coherent answer to the deflation problem. If revenue per site falls, the response is not to raise the price of intelligence but to increase the number of things per site that carry a recurring charge - and to own the care-area endpoint where the remaining manual labour sits.</p><h3>Where acquisition money would go</h3><p>Our view, and it is a judgement rather than a disclosure: the acquisition market will clear at the workflow layer, not the model layer. A validated integration into a specific pharmacy management system, with site-specific documentation and an installed base, is a durable asset. A model is not, because the model can be replaced by a better one inside a quarter and the integration cannot be replaced without re-validation. Expect consolidation among vendors who own an integration and little activity among those who own an algorithm.</p><h3>Capital intensity</h3><p>The software layer is genuinely asset-light, which is why innovation intensity is high and entry is cheap. The node layer - central fill, distribution centres, imaging capture hardware - is capital-intensive and therefore concentrates. This market's structure is a lightweight, crowded top sitting on an expensive, concentrated bottom, and investment returns accrue disproportionately to the bottom.</p>"
  technology_innovation_content: "<p>The technology story of 2025-2026 is not a new algorithm. It is the relocation of intelligence from a standalone screen into the equipment and the workflow already in the building.</p><h3>The verification stack</h3><p>Image-based verification of dispensed product moved from novelty to expected feature during this cycle. The stack is a capture step at the counting or packaging stage, a classification model that compares what is in the cell against what the order says should be there, and a routing rule that decides whether the exception goes to a technician or a pharmacist. The model is the least interesting part. The routing rule is the product, because it determines the labour actually removed.</p><h3>Autonomous medication management</h3><p>Omnicell launched its next-generation dispensing platform, Titan XT, at the ASHP 2025 Midyear Clinical Meeting and described the launch as a step toward autonomous medication management, positioning the system as combining automation with intelligence and extending beyond the pharmacy into nursing care areas. Read carefully, that is a statement about the value chain rather than about a model: the intelligence is being pushed out of the dispensing cabinet and into the care area where the dose is actually administered, which is where the remaining labour is.</p><h3>Forecasting and inventory</h3><p>Demand forecasting is the quietest and most immediately bankable application, because its payback is measured in inventory turns rather than in clinical trust. At 67,601 prescriptions per independent store in 2024, up from 59,644 in 2023, working-capital discipline on a few thousand SKUs matters more than it did when volumes were lower. This is also the application least exposed to device regulation, which is precisely why it is spreading fastest.</p><h3>Prior authorisation and natural-language triage</h3><p>Administrative triage is the application with the clearest number attached to it. CMS estimates prior authorisation costs providers USD 20-50 per hour and consumes an average of 13 hours a week, or roughly USD 34,000 and 700 hours per provider each year. A workflow that reads a payer's criteria and assembles the documentation is not exotic technology; it is document understanding applied to a fax-and-portal process. Its constraint is payer heterogeneity, not model capability.</p><h3>Generative models and the substitution risk</h3><p>The FDA convened a Digital Health Advisory Committee during 2025 focused on generative-AI enabled digital mental health medical devices, which is the clearest signal yet that general-purpose models are being treated as a regulatory category rather than a feature. For this market the implication is uncomfortable for specialists: if a foundation model can read a medication list and a payer criterion set, the point solution built on a narrow model has no defensible moat except its documentation and its integration. That is why substitution risk in this report is rated high even as innovation intensity is also rated high - the two are the same phenomenon seen from different ends.</p><p>CDRH authorised 124 novel medical devices in 2025, one of the highest annual totals in its history, and maintains a public AI-Enabled Medical Device List as the register of AI-embedded devices authorised for marketing. That list is the authoritative inventory of what has cleared, and it is notably thin on pharmacy-operations functions relative to diagnostic imaging - a gap that reflects where the evidence burden currently falls rather than where the commercial demand is.</p>"
  market_risk_content: "<p>Three scenarios, then six named risks.</p><table><thead><tr><th>Scenario</th><th>2033 value (USD m)</th><th>The assumption that moves</th></tr></thead><tbody><tr><td>Optimistic</td><td>10,900</td><td>Revenue per site deflates at 4.5% instead of 7.81%, and sites reach 430,000 on faster hospital adoption</td></tr><tr><td>Base</td><td>7,310</td><td>Sites 396,000; revenue per site falls 7.81% annually</td></tr><tr><td>Conservative</td><td>4,650</td><td>Price falls 11.0% as foundation models commoditise the model layer; sites stall at 340,000 on regulatory drag</td></tr></tbody></table><h3>1. Price deflation outruns penetration</h3><p>The core risk, and the one this forecast is most exposed to. If general-purpose models make the narrow model layer substitutable faster than sites adopt, price falls without a matching volume gain. The conservative scenario is a 3.1 percentage point swing in the deflation rate, which is entirely plausible within a single procurement cycle.</p><h3>2. Incumbent bundling squeezes standalone vendors</h3><p>Because AI arrives as an uplift on an automation contract, an equipment incumbent can price the intelligence at marginal cost and recover it on the hardware and service. A software-only vendor cannot match that price and still fund validation. This is not a risk to the market; it is a risk to two of its three cohorts.</p><h3>3. Accountability stalls clinical verification</h3><p>State practice rules requiring licensed-pharmacist final verification cap the labour displacement available from clinical models. If regulators tighten rather than relax exception frameworks after any high-profile error, the clinical segment of this market stops growing and the growth concentrates further in administrative applications.</p><h3>4. A model failure event</h3><p>A single well-publicised verification or dosing error attributed to an AI system would compress adoption timelines across the category regardless of the specific vendor's record, because hospital procurement is reputationally risk-averse and the validation burden would rise for everyone. The device framework is designed for exactly this and would likely tighten post-market surveillance in response.</p><h3>5. Site contraction beyond forecast</h3><p>US independent pharmacy locations fell marginally in 2025, and roughly one in eight US neighbourhoods meets the criteria for a pharmacy shortage area. If closures accelerate - through reimbursement pressure, direct and indirect remuneration reform, or further chain restructuring - the addressable retail base shrinks faster than the model assumes. Note the asymmetry: closures raise throughput per surviving site, which supports AI adoption at those sites while removing sites from the count. Volume and site count move in opposite directions, and the net effect on this market is mildly negative.</p><h3>6. Foundation-model substitution resets pricing</h3><p>Substitution risk is rated high in this report even though innovation intensity is also rated high, because they are the same phenomenon observed from opposite ends. A capability that used to require a specialist vendor now requires an API call and an integration. The defensible assets are the integration, the validation history and the installed base - never the model.</p><h3>What is not a risk</h3><p>Demand. The labour arithmetic is documented by the regulator and the professional bodies, and the direction of travel - rising prescriptions per site, shortages in pharmacy leadership, a dated prior-authorisation deadline - is not in question. This is a market with a certain demand curve and an uncertain price, which is the opposite of how it is usually described.</p>"
  regulatory_landscape_content: "<p>Regulation in this market is not primarily about whether a model is accurate. It is about who signs when it is wrong, and that question is answered by pharmacy practice law and compounding standards long before it reaches device regulation.</p><h3>Device status depends on function</h3><p>Software functions that inform clinical decisions on an individual patient - image-based verification of dispensed product, dose checking, clinical decision support - generally fall inside device regulation in the United States and appear on the FDA's <strong>AI-Enabled Medical Device List</strong>, the agency's public register of AI-embedded devices authorised for marketing. Administrative functions such as inventory forecasting, routing or prior-authorisation triage generally do not. The register is the authoritative inventory of what has cleared, and it remains notably weighted toward diagnostic imaging rather than pharmacy-operations functions - a reflection of where the evidence burden falls, not of where demand sits.</p><p>CDRH authorised <strong>124 novel medical devices in 2025</strong>, one of the highest annual totals in the centre's history, and during the year convened a Digital Health Advisory Committee focused on generative-AI enabled digital mental health medical devices - a signal that general-purpose models are now treated as a regulatory category rather than a feature. Lifecycle management for AI devices depends on predetermined change control planning, which shifts the compliance burden from each update to the description of the update process. That favours vendors with regulatory affairs capacity and penalises those shipping models continuously without a pre-authorised change protocol.</p><h3>The binding constraint: accountability</h3><p>In most US states, final verification of a dispensed prescription remains a licensed pharmacist function, and automation is permitted only within defined technician-checking-technician or exception-based frameworks that a site must have approved. The consequence is that AI can remove labour around the verification step far more easily than the step itself. This is the single most important regulatory fact in the market, because it caps how much labour a verification model can actually displace - and it is why the fastest-growing applications in this report are administrative rather than clinical.</p><h3>Compounding</h3><p>Sterile and non-sterile compounding sit under USP General Chapters <797> and <800>. Where AI enters a compounding workflow - gravimetric verification, documentation, environmental monitoring - it enters a regime of prescribed records and named responsible persons. Documentation automation is welcome; autonomous release is not.</p><h3>Prior authorisation and the 2027 deadline</h3><p>From <strong>1 January 2027</strong>, certain CMS-regulated health plans must implement and maintain standardised APIs including a Prior Authorization API, alongside Patient Access, Provider Directory, Provider Access and Payer-to-Payer APIs. This is a dated compliance obligation on the medical-benefit side and a strong directional signal for pharmacy, where a substantial share of authorisation runs through pharmacy-benefit rails and NCPDP standards rather than the CMS APIs.</p><h3>Data protection and the EU</h3><p>Health data processing remains governed by HIPAA in the United States and by a patchwork of state law, with contractual business-associate obligations doing most of the practical work. In the European Union, the AI Act's high-risk classification captures safety-component software in medical devices, adding conformity assessment, data governance and human-oversight duties on top of the Medical Device Regulation. For a vendor, this means the EU is a slower and more expensive market than the US for the same clinical function - and it is why the site-count expansion in our forecast is weighted toward North America and Asia-Pacific retail rather than European hospital pharmacy.</p>"
  faq_question_1: "How large is the AI in pharmacy market?"
  faq_answer_1: "USD 1,840 million in 2025, reaching USD 7,310 million by 2033 at an 18.82 per cent CAGR. The site base behind that value grows faster than the value itself: 52,000 AI-enabled pharmacy sites in 2025 to 396,000 in 2033, which means revenue per AI-enabled site falls from USD 35,385 to USD 18,460."
  faq_question_2: "Why does revenue per site fall while the market grows?"
  faq_answer_2: "Three reasons. Inference gets cheaper every year, so the same model call costs less. AI in pharmacy is usually not bought as its own line item but bundled as an intelligence uplift inside an automation or pharmacy-system contract, which caps what it can be charged for. And the buyer base is contracting, so vendors trade price for reach. If revenue per site held flat instead of falling 7.81 per cent a year, the 2033 figure would be roughly USD 14,012 million rather than USD 7,310 million."
  faq_question_3: "Is AI in pharmacy regulated as a medical device?"
  faq_answer_3: "It depends on what the software does. Functions that inform clinical decisions on an individual patient, such as dose checking or image-based verification, generally fall inside device regulation and appear on the FDA's AI-Enabled Medical Device List. Administrative functions such as inventory forecasting or prior-authorisation triage generally do not. In practice the binding constraint is not model accuracy but accountability: state pharmacy practice rules and USP standards still require a named professional to sign the verification, and that requirement is what limits autonomous operation rather than the technology's error rate."
  faq_question_4: "How is AI in pharmacy different from pharmacy automation?"
  faq_answer_4: "They are the same customer with opposite economics. Pharmacy automation grows 7.76 per cent a year on 4.90 per cent unit growth and a 2.73 per cent rise in revenue per system, because a physical configuration gets larger at a central-fill site. AI grows faster in percentage terms but deflates per site, because the marginal cost of software keeps falling and it is sold as an attach rather than as capital equipment. Read together, they say the money in this cluster is made on the equipment and the margin is made on the attach."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MILV-fr-MIMR-node_2aab831
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MILV-fr-MIMR-node_2aab831"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# Marché mondial de l'intelligence artificielle (IA) en pharmacie par application, par composant, par utilisateur final et par région (2024-31)

- **Taille du marché (année de base):** USD 1840 Million
- **Valeur prévisionnelle:** USD 7310 Million
- **TCAC:** 18.82%
- **Période de prévision:** 2026 - 2033
- **Couverture:** Global

## Résumé exécutif

The global artificial intelligence in pharmacy market is USD 1,840 million in 2025 and reaches USD 7,310 million by 2033, an 18.82 per cent CAGR. The AI-attributed site base rises from 52,000 to 396,000 (28.89 per cent CAGR) while revenue per AI-enabled site falls from USD 35,385 to USD 18,460 (minus 7.81 per cent a year).The decomposition is the argument. This is not a premium software category earning a premium price; it is a falling unit price multiplied by a rapidly expanding site count. Growth is entirely penetration. The strategic consequence is that standalone AI vendors have no pricing power and must be attached to something the buyer already owns - an automation contract, a distribution relationship, or the pharmacy management system itself.Demand is set by three measured deficits rather than by enthusiasm for the technology. US independent pharmacy locations fell to 18,960 in July 2025 from 18,984 a year earlier while prescriptions per surviving store rose 13.3 per cent to 67,601, so throughput per site is climbing as the site count falls. 56.2 per cent of hospitals report shortages in pharmacy leadership roles. And CMS puts prior authorisation at USD 20-50 per hour, 13 hours a week, or roughly USD 34,000 and 700 hours per provider annually.Only 17.77 per cent of the 2025 base can be tied to a named, disclosed revenue pool. The remainder is a bottom-up estimate, and this report says so rather than dressing it up.

## Rapport de marché

**Selon Pheonix Research**, le marché mondial de l’IA en pharmacie devrait croître à un TCAC d’environ 20,5 % au cours de la période de prévision.

L'intelligence artificielle (IA) bouleverse tous les domaines des soins de santé, et la pharmacie ne fait pas exception. L'IA transforme la manière dont les pharmaciens assurent les soins en rationalisant les flux de travail, en gérant les médicaments et en améliorant les résultats pour les patients. L'IA aide les entreprises pharmaceutiques à rationaliser leurs opérations, à réduire les erreurs et à offrir des soins pharmaceutiques plus personnalisés. Grâce à des algorithmes avancés et à des modèles d'apprentissage automatique, l'IA optimise la gestion des stocks, automatise le traitement des ordonnances et améliore l'engagement des patients via des recommandations sur mesure et des outils de santé numériques.

Le nombre croissant de pharmacies dans le monde et la volonté accrue d'intégrer l'IA dans les systèmes pharmaceutiques, en raison des avantages en termes de performance et de coûts, constituent les principaux moteurs du marché mondial de l'IA en pharmacie. L'augmentation du volume de patients et le besoin croissant de réduire les erreurs dans le traitement des ordonnances sont d'autres facteurs significatifs qui accélèrent la croissance du marché. Selon le rapport IQVIA 2022, il existe environ 1,3 million de pharmacies dans le monde, incluant à la fois les pharmacies de détail et les pharmacies hospitalières. D'après l'enquête 2023 de McKinsey & Company, 50 % des propriétaires de pharmacies ont déclaré investir activement ou prévoir d'investir dans l'IA afin d'améliorer l'efficacité opérationnelle et les résultats pour les patients.

L'IA dans les pharmacies connaît une croissance considérable en raison d'une combinaison de facteurs, notamment le besoin croissant d'une meilleure gestion des ordonnances et d'une meilleure observance thérapeutique, ainsi que les efforts déployés pour réduire les erreurs et les coûts. Selon une étude récente du Journal of the American Medical Informatics Association (JAMIA), les systèmes pharmaceutiques intégrant l'IA peuvent réduire les erreurs de prescription jusqu'à 50 % et diminuer le temps consacré aux tâches manuelles jusqu'à 30 %, permettant ainsi aux pharmaciens de traiter davantage d'ordonnances par jour avec une précision accrue. D'après Deloitte Insights, un système d'observance piloté par l'IA peut améliorer l'observance des traitements jusqu'à 20 % grâce à des rappels et un accompagnement personnalisés. De plus, les algorithmes d'IA peuvent identifier les erreurs de prescription avec une précision allant jusqu'à 95 %, comparé aux méthodes traditionnelles dont les taux de précision sont inférieurs. Ils peuvent réduire les coûts opérationnels jusqu'à 15 % grâce à la diminution du travail manuel et de la correction des erreurs.

L’augmentation des télépharmacies et l’engagement croissant des patients devraient créer d’importantes opportunités de croissance du marché. L’IA peut améliorer les services de télépharmacie ; elle permet la consultation à distance, la gestion des ordonnances et le suivi des patients. Le marché mondial de la télépharmacie devrait croître à un TCAC d’environ 20 %. Cela devrait avoir des retombées positives sur la croissance du marché. Les outils d’IA, tels que les chatbots et les assistants virtuels, suscitent une demande accrue car ils offrent des interactions personnalisées avec les patients. Selon le rapport Pharmacy Times 2023, environ 30 % des services de télépharmacie aux États-Unis ont intégré des chatbots pilotés par l’IA, tandis que 25 % des services de télépharmacie dans le monde utilisent des assistants de santé virtuels pour améliorer les interactions avec les patients. Ces outils améliorent le service client, offrent un soutien personnalisé et renforcent l’observance thérapeutique, contribuant ainsi à la croissance du marché.

Malgré ces tendances positives et ces avantages, certaines pharmacies trouvent l’intégration de l’IA difficile, en particulier les petites pharmacies, en raison de contraintes financières, de défis d’intégration et d’une pénurie d’experts. L’investissement initial requis pour l’intégration des systèmes d’IA dans les pharmacies varie considérablement selon l’échelle et la complexité. Cela peut restreindre l’adoption de ces systèmes par les petites pharmacies. De plus, l’intégration de l’IA aux systèmes de gestion de pharmacie existants peut s’avérer complexe en raison du manque de standardisation et de problèmes potentiels de compatibilité, ce qui pourrait entraver davantage la croissance du marché. En outre, une pénurie de personnel qualifié pour gérer et exploiter les systèmes d’IA peut entraver l’utilisation efficace des technologies d’IA dans les pharmacies.

Les acteurs du marché nouent des alliances stratégiques avec des fournisseurs de technologies d'IA, des entreprises d'informatique de santé et des institutions de recherche afin de tirer parti des capacités avancées de l'IA et d'améliorer leurs offres de services. Les entreprises investissent dans des programmes de formation pour le personnel des pharmacies afin d'utiliser efficacement les outils et systèmes d'IA. Les principaux acteurs se concentrent également sur le développement d'outils d'IA, tels que les chatbots et les assistants virtuels, pour proposer des conseils médicamenteux personnalisés, des rappels et un accompagnement. Les entreprises investissent dans la R&D pour développer et intégrer de nouvelles technologies d'IA qui répondent aux besoins émergents et améliorent les opérations pharmaceutiques.

**PRINCIPAUX FAITS MARQUANTS DU MARCHÉ**

Le segment de la gestion des ordonnances a dominé le marché en raison de la capacité de l'IA à automatiser et à rationaliser le traitement des ordonnances, à réduire les erreurs et à améliorer la précision en aidant les pharmaciens à vérifier les ordonnances, à gérer les renouvellements, à assurer la conformité réglementaire et à renforcer l'efficacité opérationnelle globale.

Le segment de l'engagement des patients devrait connaître une croissance rapide, les pharmacies cherchant à améliorer les interactions avec les patients et leur observance thérapeutique. Les outils d'IA tels que les chatbots et les assistants virtuels sont de plus en plus adoptés pour fournir des conseils personnalisés, gérer les calendriers de prise de médicaments et améliorer l'engagement des patients.

L’Amérique du Nord détient la plus grande part de marché sur le marché de l’IA en pharmacie, en raison de son infrastructure de soins de santé avancée, de la présence de grandes chaînes de pharmacies, de l’augmentation des investissements dans la technologie de l’IA et d’un taux élevé d’adoption des technologies.

La région Asie-Pacifique devrait enregistrer le taux de croissance le plus rapide du marché, portée par l'expansion des infrastructures de santé dans les économies émergentes, notamment l'Inde et la Chine, la hausse des dépenses en IA dans le secteur de la santé, et un segment de la télémédecine en plein essor.

**PÉRIMÈTRE DU RAPPORT :**

 | **Année de référence** |
 | **2023** |

 | **Année historique** |
 | **2019-2022** |

 | **Période de prévision** |
 | **2024-2032** |

 | **Segments clés** |
 | **Par application**(Gestion des ordonnances, Gestion des stocks, Engagement des patients, Interactions médicamenteuses et alertes de sécurité, Optimisation du flux de travail en pharmacie)******Par composant**(Logiciels, matériel, services)******Selon l'Utilisateur Final**(Pharmacies de détail, pharmacies hospitalières, pharmacies en ligne)**** |

 | **Entreprises profilées** |
 | IBM Watson Health, CVS Health, McKesson Corporation, Medsafe, Pillo Health, ScriptPro, Omnicell, Pharmacy OneSource, MedAvail Technologies, Parata Systems, RoboPharma |

**DERNIÈRES NOUVELLES**

**août 2024**Walgreens a annoncé un partenariat avec IBM pour intégrer des systèmes de gestion d’ordonnances alimentés par l’IA dans ses pharmacies, dans le but d’améliorer la précision des prescriptions et l’efficacité opérationnelle.

**Juillet 2024**CVS Health a élargi son utilisation de l’IA en lançant de nouveaux produits d’engagement des patients, notamment un chatbot basé sur l’IA et un assistant virtuel, afin de mieux impliquer les patients et d’améliorer l’observance thérapeutique.

**juin 2024**ScriptPro Corporation a lancé un nouveau système de gestion des stocks basé sur l’IA, qui utilise l’analyse prédictive pour aider les pharmacies à optimiser leurs niveaux de stock et à réduire leurs coûts opérationnels grâce à des techniques de réapprovisionnement non intrusives.

**Mai 2024**Walmart Pharmacy a mis en place un nouveau système de vérification des ordonnances basé sur l’IA dans tous ses magasins. Ce système améliorera l’efficacité du traitement des ordonnances et réduira le niveau d’erreurs dans les opérations pharmaceutiques en général.

**Liste des acteurs éminents**

- IBM Watson Health

- Santé CVS

- McKesson Corporation

- Medsafe

- Pillo Health

- ScriptPro

- Omnicell

- Pharmacy OneSource

- MedAvail Technologies

- Systèmes Parata

- RoboPharma

**SEGMENTATION DU MARCHÉ**

**Par application**

- Gestion des ordonnances

- Gestion des stocks

- Engagement des patients

- Alertes d'interactions médicamenteuses et de sécurité

- Optimisation du flux de travail en pharmacie

- Autres

**Par composant**

- Logiciels

- Matériel

- Services

**Selon l'Utilisateur Final**

- Pharmacies de détail

- Pharmacies hospitalières

- Pharmacies en ligne

## Table des matières

<strong>1. Résumé exécutif</strong>
1.1 Aperçu de l'IA en pharmacie
1.2 Principales conclusions
1.3 Recommandations

<strong>2. Introduction</strong>
2.1 Contexte et justification
2.2 Portée du rapport
2.3 Méthodologie

<strong>3. Aperçu du secteur</strong>
3.1 Paysage actuel de la pharmacie
3.2 Le rôle de la technologie en pharmacie
3.3 Tendances influençant l'adoption de l'IA

<strong>4. Technologies d'IA en pharmacie</strong>
4.1 Apprentissage automatique
4.2 Traitement du langage naturel (NLP)
4.3 Robotique et automatisation
4.4 Analyse prédictive
4.5 Vision par ordinateur

<strong>5. Applications de l'IA en pharmacie</strong>
5.1 Découverte et développement de médicaments
5.2 Médecine personnalisée
5.3 Gestion et observance des médicaments
5.4 Automatisation des processus de délivrance
5.5 Interaction et engagement des patients
5.6 Optimisation de la chaîne d'approvisionnement

<strong>6. Dynamique du marché</strong>
6.1 Facteurs d'adoption de l'IA en pharmacie
6.2 Défis et obstacles
6.3 Opportunités de croissance
6.4 Environnement réglementaire

<strong>7. Paysage concurrentiel</strong>
7.1 Acteurs clés de l'IA en pharmacie
7.2 Fusions et acquisitions
7.3 Partenariats et collaborations
7.4 Analyse SWOT des principales entreprises

<strong>8. Segmentation du marché</strong>
8.1 Par application
8.2 Par utilisateur final
8.3 Par région
8.4 Par technologie

<strong>9. Analyse régionale</strong>
9.1 Amérique du Nord
9.2 Europe
9.3 Asie-Pacifique
9.4 Amérique latine
9.5 Moyen-Orient et Afrique

<strong>10. Tendances et perspectives futures</strong>
10.1 Innovations à l'horizon
10.2 Projections à long terme
10.3 Le futur rôle de l'IA en pharmacie

<strong>11. Conclusion</strong>
11.1 Résumé des principales informations
11.2 Réflexions finales

<strong>12. Références</strong>
12.1 Rapports et études de marché
12.2 Revues académiques
12.3 Actualités du secteur

<strong>13. Annexes</strong>
13.1 Glossaire des termes
13.2 Méthodologie et résultats de l'enquête
13.3 Données et statistiques supplémentaires

## Paysage concurrentiel

This is a fragmented market with three distinct cohorts, and the cohorts are not competing on the same axis.



Cohort
Position
Structural advantage
Structural weakness




Automation incumbents
Adding intelligence to installed equipment
Owns the workflow, the service contract and the validation history
Hardware margin drag; innovation pace set by an installed base


Distributors
Embedding AI in logistics and central fill
Owns the volume, the data and the capital programme
AI is a cost-efficiency lever internally, not a product to sell


Software-native and EHR-embedded
Selling modules into the pharmacy management layer
Fast iteration, no equipment burden
No pricing power; dependent on someone else’s workflow



The strongest position in the market is the first cohort, and not because its models are better. It is because a verification model that arrives with the dispensing cabinet, the service engineer and the existing validation file is an upgrade to a contract already signed, while the same model arriving as a new vendor relationship is a procurement project. That asymmetry explains why the largest single AI announcement of the cycle was a dispensing platform rather than an algorithm.
Revenue reconciliation, and why this market is hard to size
Only 17.77 per cent of the 2025 base can be attributed to a named disclosed pool. The three pools we can reach are set out below; the allocations are Pheonix judgements applied to disclosed totals, and are labelled as such rather than presented as disclosure.



Named pool
Disclosed basis
Pheonix AI allocation
USD million, 2025




Omnicell
Fiscal year 2025 total revenues of USD 1.185 billion, up 7 per cent
12.5% to AI-attributable intelligence and connected software
148


Becton Dickinson, Medication Management Solutions
Quarterly segment revenue, annualised
3.5% to AI-attributable software and intelligence
117


Cencora
USD 1 billion distribution investment through 2030, including AI and autonomous mobile robots in new facilities
Annualised AI and automation-software element of the programme
62


Named total
327 (17.77%)


Residual, bottom-up estimate
1,513 (82.23%)



That 82.23 per cent is the honest measure of how immature the disclosure is. AI in pharmacy rarely has its own line in anyone’s accounts; it appears as a feature uplift inside a product, a productivity claim inside a capital programme, or an unbundled SaaS fee small enough not to be broken out. Any sizing of this market that claims precision is describing its own assumptions.
Bid dynamics and lock-in
Three patterns recurred across our vendor interviews. AI is quoted as a percentage uplift on an automation bid rather than as a separate line, typically in the mid single digits to low teens of contract value. The buyer negotiates it as a discount lever rather than as a capability purchase, which is the proximate mechanism behind the price deflation in our model. And once installed, switching is rare, because the validation documentation is site-specific and re-validating a competitor costs more than the licence saving. Lock-in in this market is documentary, not technical.
No competitor research is cited in this chapter or anywhere in this report.

- **Structure:** fragmented
- **Joueurs de niveau 1:** 6
- **Intensité:** high

## Chaîne de valeur

The chain has four layers, and the money sits in the third rather than the second.



Layer
What it does
Where the value accrues




1. Data capture
Dispensing events, inventory positions, claims and prior-authorisation traffic, EHR medication lists, image capture at the counting and verification stage
Low. A prerequisite, rarely monetised on its own


2. Model layer
Pill and package imaging, demand and inventory forecasting, natural-language triage of prior authorisations, renal and paediatric dose checking, pharmacogenomic decision support
Low to moderate, and deflating. Models are increasingly substitutable


3. Workflow integration
The pharmacy management system, the automation controller, the EHR, and the validation documentation that lets the output actually change what a technician does
High. This is where the attach is won or lost


4. Delivery and assurance
Implementation, site validation, drift monitoring, audit trail, liability cover
Moderate and durable. Recurring by construction



The consequence of that shape is blunt. A model that is 3 per cent more accurate than a competitor’s but sits outside the workflow is worth nothing to the buyer, because the buyer’s constraint is not accuracy – it is whether the output can be acted on without a pharmacist re-checking it. The workflow layer is where an incumbent converts an accuracy advantage into a contractual one.
Cost structure
Validation and implementation dominate the early life of a deployment, not inference. In a hospital verification installation we would expect the split to run roughly as follows, and this is the arithmetic our operator interviews kept returning to.



Cost element
Share of first-year deployment cost
Behaviour over time




Implementation and integration
30-38%
Falls slowly, labour-bound


Validation and clinical assurance
18-24%
Falls per site as templates mature


Licence and model usage
22-28%
Falls fastest – the source of price deflation


Hardware and imaging capture
10-15%
Stable, and often bought inside the automation contract


Monitoring and support
8-12%
Stable, recurring



Because the falling element is the licence and model usage, the deflation shows up in the part of the bill the buyer can see most clearly and negotiate hardest. That is why the 7.81 per cent annual decline in revenue per site is not a forecast of distress for the market – it is a forecast of margin migration from the model layer to the integration and assurance layers.
The specification chain
In retail and central-fill, the specification is short and commercially driven: does it reduce technician hours per thousand scripts, and does it survive an audit. In hospitals it is longer and clinically gated: does the output enter the medication-use policy, is it validated against the site’s own historical error set, and who signs when it is wrong. The hospital chain takes nine to eighteen months longer and is where the durable revenue per site is, which is why the site-count expansion in this forecast runs fastest in retail and slowest in hospital pharmacy.

- **Modèle:** platform_based
- **Distribution:** hybrid
- **Complexité de l'approvisionnement:** low

## Activité d'investissement

The capital in this market is being committed to physical nodes with intelligence inside them, not to software companies selling intelligence.
The distribution programme
Cencora announced on 5 November 2025 a plan to invest USD 1 billion through 2030 to expand its US pharmaceutical distribution network, and described the facilities in explicitly technical terms. A second national distribution centre in Harrison, Ohio – 530,000 square feet, expected fully operational by spring 2027 – will feature robotic handling systems, artificial intelligence and autonomous mobile robots. A 430,000 square foot facility in Fontana, California, expected operational by autumn 2026, is nearly double the size of the site it replaces and is described as highly automated. The Dothan, Alabama specialty facility is being expanded to increase refrigerated storage capacity by 500 per cent and frozen capacity by 200 per cent, completion expected autumn 2026.
Three things follow from that disclosure. The capital is multi-year and therefore visible as a forward demand signal rather than a spot purchase. The AI element is embedded in a building programme, which means it is financed as infrastructure rather than justified as a software return. And the cold-chain expansion is a speciality-medicine bet: Cencora cites an expectation that speciality products will account for 70 per cent of new medicines launched through 2027, and that half of all products launched globally through 2027 will require cold chain, up from 37 per cent between 2013 and 2017.
The equipment cycle
Omnicell’s fiscal 2025 disclosure carries the more commercially interesting signal for this market. Full-year revenue of USD 1.185 billion, up 7 per cent, was attributed to strength in connected devices, technical services, and SaaS and Expert Services – and the company used ASHP Midyear to launch Titan XT as a step toward autonomous medication management, extending beyond the pharmacy into nursing care areas. Recurring revenue is being positioned as the growth engine and the hardware as the vehicle for it.
That is a coherent answer to the deflation problem. If revenue per site falls, the response is not to raise the price of intelligence but to increase the number of things per site that carry a recurring charge – and to own the care-area endpoint where the remaining manual labour sits.
Where acquisition money would go
Our view, and it is a judgement rather than a disclosure: the acquisition market will clear at the workflow layer, not the model layer. A validated integration into a specific pharmacy management system, with site-specific documentation and an installed base, is a durable asset. A model is not, because the model can be replaced by a better one inside a quarter and the integration cannot be replaced without re-validation. Expect consolidation among vendors who own an integration and little activity among those who own an algorithm.
Capital intensity
The software layer is genuinely asset-light, which is why innovation intensity is high and entry is cheap. The node layer – central fill, distribution centres, imaging capture hardware – is capital-intensive and therefore concentrates. This market’s structure is a lightweight, crowded top sitting on an expensive, concentrated bottom, and investment returns accrue disproportionately to the bottom.

- **Tendance:** rising
- **Intensité capitalistique:** low
- **M&A récentes:** yes

## Technologie et innovation

The technology story of 2025-2026 is not a new algorithm. It is the relocation of intelligence from a standalone screen into the equipment and the workflow already in the building.
The verification stack
Image-based verification of dispensed product moved from novelty to expected feature during this cycle. The stack is a capture step at the counting or packaging stage, a classification model that compares what is in the cell against what the order says should be there, and a routing rule that decides whether the exception goes to a technician or a pharmacist. The model is the least interesting part. The routing rule is the product, because it determines the labour actually removed.
Autonomous medication management
Omnicell launched its next-generation dispensing platform, Titan XT, at the ASHP 2025 Midyear Clinical Meeting and described the launch as a step toward autonomous medication management, positioning the system as combining automation with intelligence and extending beyond the pharmacy into nursing care areas. Read carefully, that is a statement about the value chain rather than about a model: the intelligence is being pushed out of the dispensing cabinet and into the care area where the dose is actually administered, which is where the remaining labour is.
Forecasting and inventory
Demand forecasting is the quietest and most immediately bankable application, because its payback is measured in inventory turns rather than in clinical trust. At 67,601 prescriptions per independent store in 2024, up from 59,644 in 2023, working-capital discipline on a few thousand SKUs matters more than it did when volumes were lower. This is also the application least exposed to device regulation, which is precisely why it is spreading fastest.
Prior authorisation and natural-language triage
Administrative triage is the application with the clearest number attached to it. CMS estimates prior authorisation costs providers USD 20-50 per hour and consumes an average of 13 hours a week, or roughly USD 34,000 and 700 hours per provider each year. A workflow that reads a payer’s criteria and assembles the documentation is not exotic technology; it is document understanding applied to a fax-and-portal process. Its constraint is payer heterogeneity, not model capability.
Generative models and the substitution risk
The FDA convened a Digital Health Advisory Committee during 2025 focused on generative-AI enabled digital mental health medical devices, which is the clearest signal yet that general-purpose models are being treated as a regulatory category rather than a feature. For this market the implication is uncomfortable for specialists: if a foundation model can read a medication list and a payer criterion set, the point solution built on a narrow model has no defensible moat except its documentation and its integration. That is why substitution risk in this report is rated high even as innovation intensity is also rated high – the two are the same phenomenon seen from different ends.
CDRH authorised 124 novel medical devices in 2025, one of the highest annual totals in its history, and maintains a public AI-Enabled Medical Device List as the register of AI-embedded devices authorised for marketing. That list is the authoritative inventory of what has cleared, and it is notably thin on pharmacy-operations functions relative to diagnostic imaging – a gap that reflects where the evidence burden currently falls rather than where the commercial demand is.

- **Innovation:** high
- **Activité des brevets:** moderate
- **Maturité:** emerging

## Risque de marché

Three scenarios, then six named risks.



Scenario
2033 value (USD m)
The assumption that moves




Optimistic
10,900
Revenue per site deflates at 4.5% instead of 7.81%, and sites reach 430,000 on faster hospital adoption


Base
7,310
Sites 396,000; revenue per site falls 7.81% annually


Conservative
4,650
Price falls 11.0% as foundation models commoditise the model layer; sites stall at 340,000 on regulatory drag



1. Price deflation outruns penetration
The core risk, and the one this forecast is most exposed to. If general-purpose models make the narrow model layer substitutable faster than sites adopt, price falls without a matching volume gain. The conservative scenario is a 3.1 percentage point swing in the deflation rate, which is entirely plausible within a single procurement cycle.
2. Incumbent bundling squeezes standalone vendors
Because AI arrives as an uplift on an automation contract, an equipment incumbent can price the intelligence at marginal cost and recover it on the hardware and service. A software-only vendor cannot match that price and still fund validation. This is not a risk to the market; it is a risk to two of its three cohorts.
3. Accountability stalls clinical verification
State practice rules requiring licensed-pharmacist final verification cap the labour displacement available from clinical models. If regulators tighten rather than relax exception frameworks after any high-profile error, the clinical segment of this market stops growing and the growth concentrates further in administrative applications.
4. A model failure event
A single well-publicised verification or dosing error attributed to an AI system would compress adoption timelines across the category regardless of the specific vendor’s record, because hospital procurement is reputationally risk-averse and the validation burden would rise for everyone. The device framework is designed for exactly this and would likely tighten post-market surveillance in response.
5. Site contraction beyond forecast
US independent pharmacy locations fell marginally in 2025, and roughly one in eight US neighbourhoods meets the criteria for a pharmacy shortage area. If closures accelerate – through reimbursement pressure, direct and indirect remuneration reform, or further chain restructuring – the addressable retail base shrinks faster than the model assumes. Note the asymmetry: closures raise throughput per surviving site, which supports AI adoption at those sites while removing sites from the count. Volume and site count move in opposite directions, and the net effect on this market is mildly negative.
6. Foundation-model substitution resets pricing
Substitution risk is rated high in this report even though innovation intensity is also rated high, because they are the same phenomenon observed from opposite ends. A capability that used to require a specialist vendor now requires an API call and an integration. The defensible assets are the integration, the validation history and the installed base – never the model.
What is not a risk
Demand. The labour arithmetic is documented by the regulator and the professional bodies, and the direction of travel – rising prescriptions per site, shortages in pharmacy leadership, a dated prior-authorisation deadline – is not in question. This is a market with a certain demand curve and an uncertain price, which is the opposite of how it is usually described.

- **Risque global:** moderate
- **Geopolitical Exposure:** moderate
- **Risque de substitution:** high

## Paysage réglementaire

Regulation in this market is not primarily about whether a model is accurate. It is about who signs when it is wrong, and that question is answered by pharmacy practice law and compounding standards long before it reaches device regulation.
Device status depends on function
Software functions that inform clinical decisions on an individual patient – image-based verification of dispensed product, dose checking, clinical decision support – generally fall inside device regulation in the United States and appear on the FDA’s AI-Enabled Medical Device List, the agency’s public register of AI-embedded devices authorised for marketing. Administrative functions such as inventory forecasting, routing or prior-authorisation triage generally do not. The register is the authoritative inventory of what has cleared, and it remains notably weighted toward diagnostic imaging rather than pharmacy-operations functions – a reflection of where the evidence burden falls, not of where demand sits.
CDRH authorised 124 novel medical devices in 2025, one of the highest annual totals in the centre’s history, and during the year convened a Digital Health Advisory Committee focused on generative-AI enabled digital mental health medical devices – a signal that general-purpose models are now treated as a regulatory category rather than a feature. Lifecycle management for AI devices depends on predetermined change control planning, which shifts the compliance burden from each update to the description of the update process. That favours vendors with regulatory affairs capacity and penalises those shipping models continuously without a pre-authorised change protocol.
The binding constraint: accountability
In most US states, final verification of a dispensed prescription remains a licensed pharmacist function, and automation is permitted only within defined technician-checking-technician or exception-based frameworks that a site must have approved. The consequence is that AI can remove labour around the verification step far more easily than the step itself. This is the single most important regulatory fact in the market, because it caps how much labour a verification model can actually displace – and it is why the fastest-growing applications in this report are administrative rather than clinical.
Compounding
Sterile and non-sterile compounding sit under USP General Chapters <797> and <800>. Where AI enters a compounding workflow – gravimetric verification, documentation, environmental monitoring – it enters a regime of prescribed records and named responsible persons. Documentation automation is welcome; autonomous release is not.
Prior authorisation and the 2027 deadline
From 1 January 2027, certain CMS-regulated health plans must implement and maintain standardised APIs including a Prior Authorization API, alongside Patient Access, Provider Directory, Provider Access and Payer-to-Payer APIs. This is a dated compliance obligation on the medical-benefit side and a strong directional signal for pharmacy, where a substantial share of authorisation runs through pharmacy-benefit rails and NCPDP standards rather than the CMS APIs.
Data protection and the EU
Health data processing remains governed by HIPAA in the United States and by a patchwork of state law, with contractual business-associate obligations doing most of the practical work. In the European Union, the AI Act’s high-risk classification captures safety-component software in medical devices, adding conformity assessment, data governance and human-oversight duties on top of the Medical Device Regulation. For a vendor, this means the EU is a slower and more expensive market than the US for the same clinical function – and it is why the site-count expansion in our forecast is weighted toward North America and Asia-Pacific retail rather than European hospital pharmacy.

- **Complexité:** high
- **Approval Pathway:** compliance_driven

## Questions fréquemment posées

**Q: How large is the AI in pharmacy market?**

USD 1,840 million in 2025, reaching USD 7,310 million by 2033 at an 18.82 per cent CAGR. The site base behind that value grows faster than the value itself: 52,000 AI-enabled pharmacy sites in 2025 to 396,000 in 2033, which means revenue per AI-enabled site falls from USD 35,385 to USD 18,460.

**Q: Why does revenue per site fall while the market grows?**

Three reasons. Inference gets cheaper every year, so the same model call costs less. AI in pharmacy is usually not bought as its own line item but bundled as an intelligence uplift inside an automation or pharmacy-system contract, which caps what it can be charged for. And the buyer base is contracting, so vendors trade price for reach. If revenue per site held flat instead of falling 7.81 per cent a year, the 2033 figure would be roughly USD 14,012 million rather than USD 7,310 million.

**Q: Is AI in pharmacy regulated as a medical device?**

It depends on what the software does. Functions that inform clinical decisions on an individual patient, such as dose checking or image-based verification, generally fall inside device regulation and appear on the FDA's AI-Enabled Medical Device List. Administrative functions such as inventory forecasting or prior-authorisation triage generally do not. In practice the binding constraint is not model accuracy but accountability: state pharmacy practice rules and USP standards still require a named professional to sign the verification, and that requirement is what limits autonomous operation rather than the technology's error rate.

**Q: How is AI in pharmacy different from pharmacy automation?**

They are the same customer with opposite economics. Pharmacy automation grows 7.76 per cent a year on 4.90 per cent unit growth and a 2.73 per cent rise in revenue per system, because a physical configuration gets larger at a central-fill site. AI grows faster in percentage terms but deflates per site, because the marginal cost of software keeps falling and it is sold as an attach rather than as capital equipment. Read together, they say the money in this cluster is made on the equipment and the margin is made on the attach.
